•
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQ-B3525, a phosphatidylinositol 3-kinase (PI3-K) α/δ inhibitor, is set to receive priority review status for the treatment of recurrent/refractory follicular lymphoma (FL) as a third-line or later treatment option. TQ-B3525: A Dual Inhibitor Addressing Drug ResistanceTQ-B3525 is…
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced the official market launch of Soliqua (insulin glargine, lixisenatide) in China, targeting adults with type 2 diabetes (T2DM) who struggle with poor blood glucose control. This product can be integrated with other oral hypoglycemic drugs, along with diet and exercise, to enhance…
•
China-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), has submitted a Type II variation application to the European Medicines Agency (EMA) for its BCMA-targeted chimeric antigen receptor (CAR) T cell therapy, Carvykti (ciltacabtagene autoleucel). The application is supported…
•
Takeda (TYO: 4502) and HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) have provided an update on the New Drug Application (NDA) filing for Elunate (fruquintinib) with the US FDA. The FDA has granted the filing priority review status and set a Prescription Drug User Fee Act (PDUFA) date for November…
•
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a China-based pharmaceutical company, has unveiled plans to present clinical trial data for two of its drugs at the upcoming American Society of Clinical Oncology (ASCO) annual meeting. The company will showcase a Phase I clinical trial for its RET inhibitor, KL590586, in…
•
Shanghai-based BioRay Pharmaceutical Co., Ltd has announced that an investigational new drug (IND) filing has been submitted in China for its pipeline antibody drug conjugate (ADC), BRY812. The National Medical Products Administration (NMPA) has accepted the filing, marking a step forward in the potential approval of the LIV-1-targeted ADC for…
•
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to initiate a Phase I trial for its TYK2/JAK1 inhibitor pipeline candidate, AC-201. The study, which is randomized, double-blind, placebo-controlled, and involves single and multiple ascending doses, aims to…
•
China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced the imminent initiation of a Phase II clinical study for its innovative human dental pulp mesenchymal stem cell injection, developed to treat chronic periodontitis. This therapy is currently the first of its kind globally, marking a significant advancement…
•
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its in-house developed IL-11 monoclonal antibody (mAb), 9MW3811. The drug is intended for the treatment of various advanced malignant tumors and fibrotic diseases. Therapeutic Potential…
•
The Center for Drug Evaluation (CDE) website has indicated that Roche’s (SWX: ROG) Rozlytrek (entrectinib) is likely to receive priority review status for the treatment of children with NTRK fusion positive locally advanced or metastatic solid tumors. This priority review status is justified by the drug’s eligibility for conditional approval.…
•
Shanghai-based Zelixir Biotech, a leading provider of protein structure prediction and design services, has reportedly secured more than RMB 100 million (USD 14.1 million) in a Series A financing round. The funding was led by Qingdao Qingchi Venture Capital Fund, with additional investments from HM Capital, Hongfeng Investment, and Q…
•
PathoAI, a company at the forefront of intelligent pathology and examination through artificial intelligence (AI), has reportedly raised tens of millions of renminbi in an angel financing round. The funding was led by Hangzhou Taikun Equity Investment Fund Partnership, with participation from Deshi Capital. PathoAI’s Focus on AI Products and…
•
China-based urogenital cancer specialist Asieris Pharmaceuticals (SHA: 688176) has announced that it will publish the results of a Phase I clinical study at the American Society of Clinical Oncology (ASCO) annual meeting. The study combines Asieris’ APL-1202 with BeiGene Ltd’s (NASDAQ: BGNE, HKG: 6160) programmed death-1 (PD-1) inhibitor tislelizumab as…
•
China-based Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) has announced plans to raise up to RMB 1.809 billion (USD 260 million) through a private placement of 21,593,444 shares. The funds raised will be allocated to several key areas, including the construction of global headquarters and the advancement of innovation…
•
China-based Antengene Corporation Limited (HKG: 6996) has announced that its in-house discovered and developed antibody drug conjugate (ADC), ATG-022, targeting Claudin 18.2, has been granted two Orphan Drug Designations (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of gastric cancer and pancreatic cancer. This brings the…
•
US-based Mural Health has announced a strategic partnership with China-based Clinflash, both companies specializing in providing patient-focused services and solutions during the clinical trial process. This collaboration will see Mural Health leveraging Clinflash’s specialist IT capabilities to expand the capacity and global market reach of patient payments for clinical trials.…
•
Wuhan-based firm Hanx Biopharmaceuticals Inc. has announced the receipt of an Investigational New Drug (IND) approval in the US for its anti-CD47/PD-1 bispecific antibody (BsAb), HX009. The molecule is set to be assessed in a Phase Ib/II study for patients with relapsed/refractory lymphoma who have failed standard therapy. HX009’s Clinical…
•
China-based Clover Biopharmaceuticals Ltd (Clover; HKG: 2197) has announced the establishment of a commercial partnership with Keyuan Xinhai (Beijing) Medical Products Trading Co., Ltd (Kyuan Trade). The strategic alliance aims to prepare for the commercial launch of AdimFlu-S (QIS), the only imported quadrivalent seasonal influenza vaccine approved for use in…
•
China-based Minghui Pharmaceutical Inc. has announced the commencement of a first-in-human Phase Ia trial for its pipeline candidate, MHB018A. This novel fusion protein combines a humanized single domain IGF-1R antibody with a human Fc fragment, and the study aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers. MHB018A: A…